Table 2 ORs and corresponding 95% CIs for NHL by presence of hepatitis virus markers (Swiss HIV Cohort Study, 1984–2004)
From: Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study
NHL cases | Control subjects | ||||
|---|---|---|---|---|---|
Seropositivity | N | (%) | N | (%) | OR (95% CI) a |
Anti-HCV | |||||
No | 198 | (66.4) | 605 | (68.1) | 1b |
Yes | 100 | (33.6) | 284 | (32.0) | 1.05 (0.63–1.75) |
Anti-HBc | |||||
No | 101 | (34.0) | 305 | (34.4) | 1b |
Yes | 196 | (66.0) | 581 | (65.6) | 0.85 (0.61–1.18) |
HBsAg | |||||
No | 279 | (95.6) | 790 | (93.7) | 1b |
Yes | 13 | (4.5) | 53 | (6.3) | 0.62 (0.32–1.20) |
